Biological Role of Tumor/Stromal CXCR4-CXCL12-CXCR7 in MITO16A/MaNGO-OV2 Advanced Ovarian Cancer Patients.
CXCR4-CXCL12-CXCR7 axis
chemokine
ovarian cancer
prognosis
tumor microenvironment
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
06 Apr 2022
06 Apr 2022
Historique:
received:
10
02
2022
revised:
07
03
2022
accepted:
01
04
2022
entrez:
12
4
2022
pubmed:
13
4
2022
medline:
13
4
2022
Statut:
epublish
Résumé
This study investigated the prognostic role of the CXCR4-CXCL12-CXCR7 axis in advanced epithelial ovarian cancer (EOC) patients receiving first-line treatment within the MITO16A/MaNGO-OV2 phase-IV trial. CXCR4-CXCL12-CXCR7 expression was evaluated in the epithelial and stromal component of 308 EOC IHC-stained tumor samples. The statistical analysis focused on biomarkers' expression, their association with other variables and prognostic value. Zero-inflated tests, shrinkage, bootstrap procedures, and multivariable models were applied. The majority of EOC (75.0%) expressed CXCR4 and CXCR7, 56.5% expressed the entire CXCR4-CXCL12-CXCR7 axis, while only 4.6% were negative for CXCL12 and its cognate receptors, in regard to the epithelial component. Stromal CXCL12 and CXCR7, expressed in 11.2% and 65.5%, respectively, were associated with the FIGO stage. High CXCL12 in epithelial cancer cells was associated with shorter progression-free and overall survival. However, after adjusting for overfitting due to best cut-off multiplicity testing, the significance was lost. This is a wide-ranging, prospective study in which CXCR4-CXCL12-CXCR7 were systematically evaluated in epithelial and stromal components, in selected stage III-IV EOC. Although CXCL12 was not prognostic, epithelial expression identified high-risk FIGO stage III patients for PFS. These data suggest that it might be worth studying the CXCL12 axis as a therapeutic target to improve treatment efficacy in EOC patients.
Identifiants
pubmed: 35406620
pii: cancers14071849
doi: 10.3390/cancers14071849
pmc: PMC8997727
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Italian Association for Cancer Research
ID : IG 18921
Organisme : Ministero della Salute
ID : Ricerca Corrente grant M2/7
Références
Antivir Chem Chemother. 2019 Jan-Dec;27:2040206619829382
pubmed: 30776910
Clin Cancer Res. 2016 Jun 15;22(12):3025-36
pubmed: 27306793
Br J Cancer. 2007 Feb 12;96(3):485-91
pubmed: 17245339
Stat Med. 2004 Jun 15;23(11):1701-13
pubmed: 15160403
Sci Rep. 2020 Mar 3;10(1):3914
pubmed: 32127601
JAMA Oncol. 2017 Dec 1;3(12):e173290
pubmed: 29049607
N Engl J Med. 2018 Dec 27;379(26):2495-2505
pubmed: 30345884
Ann Oncol. 2013 Oct;24 Suppl 6:vi24-32
pubmed: 24078660
Int J Gynecol Cancer. 2021 Jun;31(6):875-882
pubmed: 33931498
Ann Oncol. 2019 May 1;30(5):672-705
pubmed: 31046081
Int J Cancer. 2008 Jan 1;122(1):91-9
pubmed: 17893878
JAMA. 2011 Jun 8;305(22):2295-303
pubmed: 21642681
Oncogene. 2017 Feb 9;36(6):840-849
pubmed: 27669436
Gene Ther. 2017 Oct;24(10):621-629
pubmed: 28753202
Cancer. 2019 Dec 15;125 Suppl 24:4563-4572
pubmed: 31967683
Int J Nanomedicine. 2020 Aug 07;15:5701-5718
pubmed: 32848392
Cancers (Basel). 2021 Oct 14;13(20):
pubmed: 34680301
Mol Ther Nucleic Acids. 2020 Jun 5;20:621-638
pubmed: 32353736
J Clin Oncol. 2007 Jul 10;25(20):2909-20
pubmed: 17617522
BMC Cancer. 2011 Mar 16;11:97
pubmed: 21410972
Nat Genet. 2020 Jun;52(6):582-593
pubmed: 32483290
FASEB J. 2019 May;33(5):6596-6608
pubmed: 30802149
Gynecol Oncol. 2017 Feb;144(2):256-259
pubmed: 27993479
Lancet Oncol. 2021 May;22(5):620-631
pubmed: 33743851
Int J Gynecol Cancer. 2021 Oct;31(10):1348-1355
pubmed: 34462317
Future Oncol. 2020 Nov;16(32):2619-2633
pubmed: 32804554
Nat Commun. 2018 Mar 13;9(1):1056
pubmed: 29535360
Cells. 2020 Apr 07;9(4):
pubmed: 32272732
Nat Rev Cancer. 2009 Jun;9(6):415-28
pubmed: 19461667
Mol Cancer Ther. 2018 Feb;17(2):532-543
pubmed: 29146630
Int J Cancer. 2018 Jan 15;142(2):281-289
pubmed: 28929490
Biopreserv Biobank. 2013 Apr;11(2):124-8
pubmed: 23840925
Hum Pathol. 2007 Nov;38(11):1676-87
pubmed: 17707463
Br J Cancer. 2012 Mar 27;106(7):1306-13
pubmed: 22415233
Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3360-5
pubmed: 17360651
Int J Cancer. 2006 Feb 15;118(4):879-88
pubmed: 16152587
Mol Ther Oncolytics. 2019 Jul 03;14:233-245
pubmed: 31384667
Mol Carcinog. 2019 Jan;58(1):144-155
pubmed: 30259564
J Biol Chem. 2005 Oct 21;280(42):35760-6
pubmed: 16107333
Cancer Res. 2005 Jan 15;65(2):465-72
pubmed: 15695388
Cancer Res. 2001 Jul 1;61(13):4961-5
pubmed: 11431324
Gynecol Oncol. 2006 Oct;103(1):226-33
pubmed: 16631235
Science. 2018 Mar 23;359(6382):1350-1355
pubmed: 29567705